EN 
ES About us
Peruvian company focused on improving access to healthcare
through innovative products and strategic services.
Who We Are
20 years connecting innovation, quality, and
partnerships to transform healthcare in Peru.
We are a Peruvian company with a strong track record in managing pharmaceutical products and services. Since 2005, we have brought innovative therapeutic solutions to the healthcare system, including medicines for rare and orphan diseases. We operate under the highest quality standards, such as GMP, GDP, and pharmacovigilance, ensuring safety, efficiency, and regulatory compliance. We are committed to providing access to cutting-edge treatments and high-impact institutional supply. Today, we continue to be the strategic partner for those aiming to transform healthcare in Peru.
Our corporate philosophy defines us as
leaders in the Peruvian and Latin
American markets.
Our Vision
To be a leading company in the Peruvian healthcare sector, recognized for our management capabilities, constant innovation, and commitment to providing access to high-value therapies, building trust with both healthcare professionals and the institutions we provide serve.
Our Mision
To continuously contribute to improving the quality of life of patients in Peru through the responsible and timely distribution of innovative, high-quality medicines. We work closely with healthcare institutions and professionals, ensuring access to therapeutic solutions that create a positive impact on medical care.
Our Values
Regulatory compliance: We respect laws and authorities in all our actions.
Punctuality and respect: We value everyone’s time and dignity.
Customer focus: We are committed to meeting your needs and satisfaction.
Social responsibility: We act ethically with awareness of our community impact.
Continuous innovation: We constantly improve through development and new ideas.
Training and perseverance: We promote ongoing learning and consistent effort.
Our achievements motivate
and drive us forward.
Our work marked a turning point in public
management of this condition, laying the foundation
for current national programs.
We introduced Crysvita®, the first treatment for XLH with guaranteed public access. We enabled over 72 pediatric transplants using unique cell therapy technology in Peru. For 7 years, we supplied factors VIII, IX, and von Willebrand for Hemophilia A and B to MINSA and EsSalud, marking a turning point in public management of this condition.
Burosumab
In 2023, we introduced Crysvita®, the world’s first and only monoclonal antibody approved for the treatment of X-linked hypophosphatemic rickets (XLH), marking a milestone in rare disease care in the country.
Transplants
More than 72 haploidentical transplants in pediatric patients with unrelated donors were made possible thanks to our high-precision magnetic cell separation products—a unique technology in the country—specialized for leukemias and aplastic anemia syndromes.
Supplying
For over 7 years, we were pioneers in supplying clotting factors for the prophylactic treatment of Hemophilia A and B at MINSA and EsSalud. Our work marked a turning point in public management of this condition, laying the foundation for current national programs.
Our Partners
Driving innovation and transforming
healthcare in Peru and Latin America
Please enter your inquiry
Please fill out the form below with your information and your company’s details. Then, leave us a comment if you wish and click the “Send” button. We assure you that your inquiry is important to us and will be addressed as soon as possible.